Circulating Biomarkers In Migraine. New Opportunities For Precision Medicine

Research output: Contribution to journalArticle

Abstract

Background Migraine is the most common neurological disorder and the second most disabling human condition, whose pathogenesis is favored by a combination of genetic, epigenetic, and environmental factors. In recent years, several efforts have been made to identify reliable biomarker(s) useful to monitor disease activity and/or ascertain the response to a specific treatment. Objective To review the current evidence on the potential biological markers associated with migraine. Methods A structured search of peer-reviewed research literature was performed by searching major publications databases up to December 2017. Results Several circulating biomarkers have been proposed as diagnostic or therapeutic tools in migraine, mostly related to migraine's inflammatory pathophysiological aspects. Nonetheless, their detection is still a challenge for the scientific community, reflecting, at least in part, disease complexity and clinical diagnostic limitations. At the present time, calcitonin gene-related peptide (CGRP) represents probably the most promising candidate as a diagnostic and/or therapeutic biomarker, as its plasma levels are elevated during migraine attack and decrease during successful treatment. Other molecules (including some neuropeptides, cytokines, adipokines, or vascular activation markers) despite promising, do not possess the sufficient prerequisites to be considered as migraine biomarkers. Conclusion The characterization of migraine specific biomarkers would be fundamental in a perspective of precision medicine, enabling risk assessment and tailored treatments. However, speculating on the clinical validity of migraine biomarkers may be premature and controlled clinical trials are presently needed to investigate both the diagnostic and therapeutic value of these biomarkers in migraine.

Original languageEnglish
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - Jun 22 2018

Fingerprint

Precision Medicine
Biomarkers
Migraine Disorders
Medicine
Therapeutics
Adipokines
Calcitonin Gene-Related Peptide
Neuropeptides
Risk assessment
Controlled Clinical Trials
Nervous System Diseases
Epigenomics
Chemical activation
Cytokines
Blood Vessels
Publications
Plasmas
Molecules
Databases

Cite this

@article{e9f8279386464b148ba484f6aee930d7,
title = "Circulating Biomarkers In Migraine. New Opportunities For Precision Medicine",
abstract = "Background Migraine is the most common neurological disorder and the second most disabling human condition, whose pathogenesis is favored by a combination of genetic, epigenetic, and environmental factors. In recent years, several efforts have been made to identify reliable biomarker(s) useful to monitor disease activity and/or ascertain the response to a specific treatment. Objective To review the current evidence on the potential biological markers associated with migraine. Methods A structured search of peer-reviewed research literature was performed by searching major publications databases up to December 2017. Results Several circulating biomarkers have been proposed as diagnostic or therapeutic tools in migraine, mostly related to migraine's inflammatory pathophysiological aspects. Nonetheless, their detection is still a challenge for the scientific community, reflecting, at least in part, disease complexity and clinical diagnostic limitations. At the present time, calcitonin gene-related peptide (CGRP) represents probably the most promising candidate as a diagnostic and/or therapeutic biomarker, as its plasma levels are elevated during migraine attack and decrease during successful treatment. Other molecules (including some neuropeptides, cytokines, adipokines, or vascular activation markers) despite promising, do not possess the sufficient prerequisites to be considered as migraine biomarkers. Conclusion The characterization of migraine specific biomarkers would be fundamental in a perspective of precision medicine, enabling risk assessment and tailored treatments. However, speculating on the clinical validity of migraine biomarkers may be premature and controlled clinical trials are presently needed to investigate both the diagnostic and therapeutic value of these biomarkers in migraine.",
author = "Patrizia Ferroni and Piero Barbanti and Antonella Spila and Federica Fratangeli and Cinzia Aurilia and Luisa Fofi and Gabriella Egeo and Fiorella Guadagni",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "6",
day = "22",
doi = "10.2174/0929867325666180622122938",
language = "English",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Circulating Biomarkers In Migraine. New Opportunities For Precision Medicine

AU - Ferroni, Patrizia

AU - Barbanti, Piero

AU - Spila, Antonella

AU - Fratangeli, Federica

AU - Aurilia, Cinzia

AU - Fofi, Luisa

AU - Egeo, Gabriella

AU - Guadagni, Fiorella

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/6/22

Y1 - 2018/6/22

N2 - Background Migraine is the most common neurological disorder and the second most disabling human condition, whose pathogenesis is favored by a combination of genetic, epigenetic, and environmental factors. In recent years, several efforts have been made to identify reliable biomarker(s) useful to monitor disease activity and/or ascertain the response to a specific treatment. Objective To review the current evidence on the potential biological markers associated with migraine. Methods A structured search of peer-reviewed research literature was performed by searching major publications databases up to December 2017. Results Several circulating biomarkers have been proposed as diagnostic or therapeutic tools in migraine, mostly related to migraine's inflammatory pathophysiological aspects. Nonetheless, their detection is still a challenge for the scientific community, reflecting, at least in part, disease complexity and clinical diagnostic limitations. At the present time, calcitonin gene-related peptide (CGRP) represents probably the most promising candidate as a diagnostic and/or therapeutic biomarker, as its plasma levels are elevated during migraine attack and decrease during successful treatment. Other molecules (including some neuropeptides, cytokines, adipokines, or vascular activation markers) despite promising, do not possess the sufficient prerequisites to be considered as migraine biomarkers. Conclusion The characterization of migraine specific biomarkers would be fundamental in a perspective of precision medicine, enabling risk assessment and tailored treatments. However, speculating on the clinical validity of migraine biomarkers may be premature and controlled clinical trials are presently needed to investigate both the diagnostic and therapeutic value of these biomarkers in migraine.

AB - Background Migraine is the most common neurological disorder and the second most disabling human condition, whose pathogenesis is favored by a combination of genetic, epigenetic, and environmental factors. In recent years, several efforts have been made to identify reliable biomarker(s) useful to monitor disease activity and/or ascertain the response to a specific treatment. Objective To review the current evidence on the potential biological markers associated with migraine. Methods A structured search of peer-reviewed research literature was performed by searching major publications databases up to December 2017. Results Several circulating biomarkers have been proposed as diagnostic or therapeutic tools in migraine, mostly related to migraine's inflammatory pathophysiological aspects. Nonetheless, their detection is still a challenge for the scientific community, reflecting, at least in part, disease complexity and clinical diagnostic limitations. At the present time, calcitonin gene-related peptide (CGRP) represents probably the most promising candidate as a diagnostic and/or therapeutic biomarker, as its plasma levels are elevated during migraine attack and decrease during successful treatment. Other molecules (including some neuropeptides, cytokines, adipokines, or vascular activation markers) despite promising, do not possess the sufficient prerequisites to be considered as migraine biomarkers. Conclusion The characterization of migraine specific biomarkers would be fundamental in a perspective of precision medicine, enabling risk assessment and tailored treatments. However, speculating on the clinical validity of migraine biomarkers may be premature and controlled clinical trials are presently needed to investigate both the diagnostic and therapeutic value of these biomarkers in migraine.

U2 - 10.2174/0929867325666180622122938

DO - 10.2174/0929867325666180622122938

M3 - Article

C2 - 29932027

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

ER -